Third, to understand the impact of Afatinib-target engagement on PTM-mediated signaling pathways, the decryptM profiles8 of the EGFR-driven carcinoma cell line A431 were reprocessed by CurveCurator (19,596 dose–response curves: 5% down-regulated, 1% up-regulated, 46% not regulated; Fig. 5c). This evidence concerns the gene EGFR and carcinoma.